Results 81 to 90 of about 4,182 (143)

Pfizer-BioNTech COVID-19 vaccine : standing orders for administering vaccine to persons 12 years of age and older : September, 28, 2021 [PDF]

CS321570-Hstanding-orders ...

core  

Attitudes of family medicine residents in Ankara towards COVID-19 vaccines administered in Turkey: a descriptive, cross-sectional study

Family Medicine & Primary Care Review, 2022
Hüsna Sarıca Çevik, Rana Baykan, Ayşe Ceyhun Peker, Selda Tekiner   +3 more
doaj   +1 more source

Safety of two-dose schedule of COVID-19 adsorbed inactivated vaccine (CoronaVac; Sinovac/Butantan) and heterologous additional doses of mRNA BNT162b2 (Pfizer/BioNTech) in immunocompromised and immunocompetent individuals”,

Immunocompromised individuals were considered high-risk for severe disease due to SARS COV-2 infection. This study aimed to describe the safety of two doses of COVID-19 adsorbed inactivated vaccine (CoronaVac; Sinovac/Butantan), followed by additional ...
Miyaji, Karina Takesaki
core   +1 more source

Safety & immunogenicity booster (3rd) dose BNT162b2 (10 \ub5g) 5 to <12 y olds study C4591007 [PDF]

slides-2022-05-19/05-COVID-Sabharwal-508 ...

core  

Impact of SARS-CoV-2 Breakthrough Infection on Short-Term CD4 Count Among Adults With HIV in the United States From 2020 to 2022. [PDF]

Open Forum Infect Dis
Hopkins L, Humes E, Gordon KS, Marconi VC, Lang R, Horberg MA, Napravnik S, Silverberg MJ, Browne LE, Park LS, Gebo KA, Agil DM, Althoff KN, Coburn SB.   +13 more
europepmc   +1 more source

Updates to the Evidence to Recommendation Framework : Pfizer-BioNTech COVID-19 booster in children aged 5-11 years [PDF]

06-COVID-Oliver-508 ...

core  

Acute tubulointerstitial nephritis following a coronavirus disease 2019 vaccine booster dose: a pediatric case report. [PDF]

CEN Case Rep
Sakaguchi H, Hirano D, Takemasa Y, Hiwatari Y, Yoshizawa S, Shoji Y, Saito A, Umeda C, Miwa S, Ito A, Oishi K.   +10 more
europepmc   +1 more source

Acquired Pure Red Cell Aplasia Following BNT162b2 mRNA COVID-19 Vaccination. [PDF]

Intern Med
Hayase N, Kaneda Y, Fukuno K, Kanemura N.   +3 more
europepmc   +1 more source

BNT162b2 2024-2025 Vaccine Effectiveness Against COVID-19 in Children Aged 6 Months-17 Years. [PDF]

J Pediatric Infect Dis Soc
Tartof SY, Ahi T, Frankland TB, Slezak JM, Zamparo JM, Ackerson BK, Puzniak L.   +6 more
europepmc   +1 more source

Impact of chronic cholecalciferol supplementation and vitamin D status on risk of post-vaccination SARS-CoV-2 breakthrough infection. [PDF]

Endocrine
di Filippo L, Bolamperti S, Campaniolo M, Gifuni L, Giustina A.   +4 more
europepmc   +1 more source